Credit Suisse disclosed Sarepta Therapeutics (NASDAQ:SRPT), hiking its price target to $68.00 earlier today
- Updated: October 18, 2016
Just yesterday Sarepta Therapeutics (NASDAQ:SRPT) traded 3.78% higher at $48.94. Sarepta Therapeutics’s 50-day moving average is $45.66 and its 200-day average is $26.92. With the last close up 88.69% relative to the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,999,959 shares of the stock were exchanged, down from an avg. volume of 4,126,920
Indicating a possible upside of 0.39%, Credit Suisse bumped up the target of Sarepta Therapeutics (NASDAQ:SRPT) to $68.00
Previously on 10/10/2016, Wedbush reported on Sarepta Therapeutics (NASDAQ:SRPT) raised the target price from $66.00 to $72.00. At the time, this indicated a possible upside of 0.24%.
With a total market value of $0, Sarepta Therapeutics has with a 52 week low of $8.00 and a 52 week high of $63.73 .
In addition to Credit Suisse reporting its stock price target, a total of 13 brokers have issued a research note on the company. The average stock price target is $20.77 with 3 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 5 brokers rating the stock a hold, 4 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.
General Information About Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.